OTC Medicines

Browse OTC Medicines Content

CHPA appreciates the opportunity to provide comments on the Alternative Database Rule Proposal that has been made by Commissioners Anne Northup and Nancy Nord.

Nov 16, 2010

This report examines the role of OTC medicines in the U.S. healthcare system as reflected through professional treatment guidelines, medication use data, as well as clinical and consumer research.

Oct 1, 2010

CHPA does not believe scheduling of dextromethorphan under the Controlled Substances Act is warranted. The prevalence and scope of reported abuse is limited. CHPA believes that there are more effective interventions to address OTC cough medicine abuse.

Sep 14, 2010

CHPA and its members support the Transparency Initiative and support FDA's goal of facilitating transparency that promotes public health and innovation, while maintaining confidentiality of trade secrets and individually identifiable patient information.

Jul 20, 2010

In order to ensure the continued safe reporting of adverse events associated with our member's products and prevent consumer confusion, we strongly believe OTC and dietary supplement product incident reports should not be included in the CPSC safety incident database.

Jul 20, 2010

Today, the manufacturers of OTC medicines containing pseudoephedrine call on Congress to improve the Combat Methamphetamine Epidemic Act by requiring a unified, national electronic tracking system to block illegal sales of PSE‐containing medicines.

Apr 13, 2010

In this submission the task group provides updated data on the safety of counterirritants administered via patched or other novel dosage forms.

Feb 16, 2010

CHPA and its member companies have an interest and expertise in dosage delivery devices and support FDA's efforts to develop guidance for industry on this important topic.

Feb 2, 2010

Filter Results